SkyePharma (Jersey) Limited - Publication of Prospectus

LONDON, UK, 30 November 2012 - SkyePharma PLC (LSE: SKP) announces that SkyePharma (Jersey) Limited has today published a prospectus in order to effect the listing of its £14,764,007 6.5 per cent. Guaranteed Bonds due 2024, which were issued on 24 September 2012.

A copy of the prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do

For further information, please contact:

SkyePharma PLC

Peter Grant, Chief Executive Officer                                                 +44 207 881 0524

FTI Consulting

Jonathan Birt /Julia Phillips/Susan Stuart                                             +44 207 831 3113

About SkyePharma

Using its multiple drug delivery technologies and expertise, SkyePharma creates enhanced versions of pharmaceutical products. The Group receives revenues from thirteen approved products in the areas of inhalation, oral, topical and injectable delivery as well as generating income from the development of further products and technology licenses. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com.